Harbin Pharmaceutical Group Co., Ltd. General Pharmaceutical Factory

China

Back to Profile

1-3 of 3 for Harbin Pharmaceutical Group Co., Ltd. General Pharmaceutical Factory Sort by
Query
Aggregations
Jurisdiction
        World 2
        United States 1
IPC Class
C07D 461/00 - Heterocyclic compounds containing indolo [3, 2, 1-d, e] pyrido [3, 2, 1-i, j] [1, 5]-naphthyridine ring systems, e.g. vincamine 3
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or 3
A61P 25/08 - AntiepilepticsAnticonvulsants 2
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis 2
A01N 43/42 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings condensed with carbocyclic rings 1
See more
Found results for  patents

1.

SALT AND CRYSTAL OF DIAZA-BENZOFLUORANE COMPOUND

      
Application Number CN2017095762
Publication Number 2018/024225
Status In Force
Filing Date 2017-08-03
Publication Date 2018-02-08
Owner HARBIN PHARMACEUTICAL GROUP CO., LTD. GENERAL PHARMACEUTICAL FACTORY (China)
Inventor
  • Lu, Qingqing
  • Shi, Shenyi
  • Bai, Tiezhong
  • Yuan, Shujie
  • Li, Zhengwu
  • Hu, Qiaofen
  • Cao, Yijie
  • Gao, Jing
  • Ding, Hui
  • Li, Jinhua
  • Xu, Guanghai
  • Wang, Zheng
  • Jin, Xin

Abstract

Disclosed are a hydrochloride, citrate, phosphate or sulfate of compound 1, a crystal of the salt, a preparation method therefor, and applications of the salt and crystal in preparing a medicament for treating cerebral stroke or epilepsy.

IPC Classes  ?

  • C07D 461/00 - Heterocyclic compounds containing indolo [3, 2, 1-d, e] pyrido [3, 2, 1-i, j] [1, 5]-naphthyridine ring systems, e.g. vincamine
  • C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
  • A61K 31/4375 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring hetero atom, e.g. quinolizines, naphthyridines, berberine, vincamine
  • A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
  • A61P 25/08 - AntiepilepticsAnticonvulsants

2.

Diaza-benzofluoranthrene compounds

      
Application Number 15548776
Grant Number 10017507
Status In Force
Filing Date 2016-02-02
First Publication Date 2018-01-18
Grant Date 2018-07-10
Owner HARBIN PHARMACEUTICAL GROUP CO., LTD. GENERAL PHARMACEUTICAL FACTORY (China)
Inventor
  • Yuan, Shujie
  • Yang, Xinchun
  • Zhao, Jinlong
  • Zhang, Daoxu
  • Sun, Mingda
  • Liu, Jiaji
  • Wei, Tao
  • Zhao, Huanan
  • Luo, Yunfu
  • Yang, Chundao

Abstract

Disclosed are a series of diaza-benzofluoranthrene compounds. The present invention particularly relates to a compound represented by formula (I), pharmaceutically acceptable salts or tautomers thereof.

IPC Classes  ?

  • A01N 43/42 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings condensed with carbocyclic rings
  • A61K 31/44 - Non-condensed pyridinesHydrogenated derivatives thereof
  • C07D 461/00 - Heterocyclic compounds containing indolo [3, 2, 1-d, e] pyrido [3, 2, 1-i, j] [1, 5]-naphthyridine ring systems, e.g. vincamine
  • C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or

3.

DIAZA-BENZOFLUORANTHRENE COMPOUNDS

      
Application Number CN2016073143
Publication Number 2016/124129
Status In Force
Filing Date 2016-02-02
Publication Date 2016-08-11
Owner HARBIN PHARMACEUTICAL GROUP CO., LTD. GENERAL PHARMACEUTICAL FACTORY (China)
Inventor
  • Yuan, Shujie
  • Yang, Xinchun
  • Zhao, Jinlong
  • Zhang, Daoxu
  • Sun, Mingda
  • Liu, Jiaji
  • Wei, Tao
  • Zhao, Huanan
  • Luo, Yunfu
  • Yang, Chundao

Abstract

Disclosed are a series of diaza-benzofluoranthrene compounds. The present invention particularly relates to a compound represented by formula (I), pharmaceutically acceptable salts or tautomers thereof.

IPC Classes  ?

  • C07D 461/00 - Heterocyclic compounds containing indolo [3, 2, 1-d, e] pyrido [3, 2, 1-i, j] [1, 5]-naphthyridine ring systems, e.g. vincamine
  • C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
  • A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
  • A61P 25/08 - AntiepilepticsAnticonvulsants